Flanagan LJ, Simmons AP, Vehige J, Willcox DPM, Garrett Q. Role
of carnitine in disease. Nutr Metab 2010; 7:30.
2. Oyanagi E, Yano H, Uchida M, Utsumi K, Sasaki J. Protective action of l-carnitine on cardiac mitochondrial function and structure against fatty acid stress. Biochem Biophys Res Commun 2011; 412: 61-67.
3. Şıktar E, Ekinci D, Şıktar E, Beydemir S, Gülçin I, Günay M. Protective role of L-carnitine supplementation against exhaustive exercise induced oxidative stress in rats. Eur J Pharmacol 2011; 668:407–413.
4. Neely JR, Morgan HE. Relationship between carbohydrate and lipid metabolism and the energy balance of heart muscle. Ann Rev Physiol 1974; 36:413-459.
5. Arsenian MA. Carnitine and its derivatives in cardiovascular disease. Prog Cardiovasc Dis 1997; 40:265-286.
6. Ferrari R, Merli E, Cicchitelli G, Mele D, Fucili A, Ceconi C. Therapeutic effects of L-carnitine on cardiovascular diseases. Ann NY Acad Sci 2004; 1033:79-91.
7. Calo AL, Pagnin E, Davis AP, Semplicini A, Nicolai R, Calvani M,
et al.
Antioxidant effect of l-carnitine and its short chain esters Relevance for the protection from oxidative stress related cardiovascular damage. Int J Cardiol 2006; 107:54-60.
8. Arsenian MA, New PS, Cafasso CM. Safety, tolerability, and efficacy of a glucose-insulin-potassium-magnesium-carnitine solution in acute myocardial infarction. Am J Cardiol 1996; 78:477-479.
9. Lopaschuk G. Regulation of carbohydrate metabolism in ischemia and reperfusion. Am Heart J 2000; 139:S115-119.
10. Lango R, Smolenski RT, Narkiewicz M, Suchorzewska J, Lysiak- Szydlowska W. Influence of L-carnitine and its derivatives on myocardial metabolism and function in ischemic heart disease and during cardiopulmonary bypass. Cardiovasc Res 2001; 51:21- 29.
11. Cui J, Das DK, Bertelli A, Tosaki A. Effects of L-carnitine and its derivatives on postischemic cardiac function, ventricular fibrillation and necrotic and apoptotic cardiomyocyte death in isolated rat hearts. Mol Cell Biochem 2003; 254:227-234.
12. Najafi M, Garjani A. The effect of L-carnitine on arrhythmias in the ischemic rat heart. Iran J Basic Med Sci 2005; 8:38-44.
13. Najafi M, Garjani A, Maleki N, Eteraf Oskouei T. Antiarrhythmic and Arrhythmogenic Effects of L-Carnitine in Ischemia and Reperfusion. Bull Exp Biol Med 2008; 146:210-21 3.
14. Najafi M, Javidnia A, Ghorbani-Haghjo A, Mohammadi S, Garjani A. Pharmacological Preconditioning with L-carnitine: Relevance to Myocardial Hemodynamic Function and Glycogen and Lactate Content. Pak J Pharm Sci 2010; 23: 250-255.
15. Najafi M, Ghaffary S, Shaseb E. Effects of Acetyl-L-Carnitine on Cardiac Arrhythmias and Infarct Size in Ischemic-Reperfused Isolated Rat Heart. Iran J Basic Med Sci 2010; 13:216-222.
16. Zacharowski K, Blackburn B, Thiemermann C. Ranolazine, A partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat. Eur J Pharmacol 2001; 418:105-110.
17. Hausenloy JD, Duchen RM, Yellon MD. Inhibiting mitochondrial permeability transition pore opening at reperfusion protects against ischemia–reperfusion injury. Cardiovasc Res 2003; 60:617–625.
18. Yamada KA, Kanter EM, Newatia A. Long-chain acylcarnitine induces Ca
2+
efflux from the sarcoplasmic reticulum. J Cardiovasc Pharmacol 2000; 36:14–21.
19. Clarke B, Wyatt KM, May GR, McCormack JG. On the roles of long chain acyl carnitine accumulation and impaired glucose utilization in ischemic contracture development and tissue damage in the guinea-pig heart. J Mol Cell Cardiol 1996; 28:171–181.
20. Wu J, Corr PB. Palmitoylcarnitine increases [Na
+
]i and initiates transient inward current in adult ventricular myocytes. Am J Physiol. 1995; 268: H2405–2417.
21. Haigney MCP, Lakatta EG, Stern MD, Silverman HS. Sodium channel blockade reduces hypoxic sodium loading and sodium dependent calcium loading. Circulation 1994; 90:391–399.
22. Singh RB, Niaz MA, Agarwal P, Beegum R, Rastogi SS, Sachan DS. A randomised, double-blind, placebo-controlled trial of L-carnitine in suspected acute myocardial infarction. Postgrad Med J 1996; 72:45-50.
23. Xue YZ, Wang LX, Liu HZ, Qi XW, Wang XH, Ren HZ. L-carnitine as an adjunct therapy to percutaneous coronary intervention for non-ST elevation myocardial infarction. Cardiovasc Drugs Ther 2007; 21:445-448.
24. Keller VA, Toporoff B, Raziano RM, Pigott JD, Mills NL. Carnitine supplementation improves myocardial function in hearts from ischemic diabetic and euglycemic rats. Ann Thorac Surg 1998; 66:1600-1603.
25. Broderick TL, Panagakis G, DiDomenico D, Gamble J, Lopaschuk GD, Shug AL,
et al
. L-carnitine improvement of cardiac function is associated with a stimulation in glucose but not fatty acid metabolism in carnitine-deficient hearts. Cardiovasc Res 1995; 30:815-820.
26. Broderick TL, Cifuentes J, Green D, Paulson DJ. Short-term carnitine deficiency does not alter aerobic rat heart function but depresses reperfusion recovery after ischemia. Can J Physiol Pharmacol 2001; 79:892-897.
27. Colonna P, Iliceto S. Myocardial infarction and left ventricular remodeling: results of the CEDIM trial, Carnitine Ecocardiografia Digitalizzata Infarto Miocardico. Am Heart J 2000; 139:S124-130.
28. Tarantini G, Scrutinio D, Bruzzi P, Boni L, Rizzon P, Iliceto S. Metabolic treatment with L-carnitine in acute anterior ST segment elevation myocardial infarction. A randomized controlled trial. Cardiology 2006;106:215-223.
)